{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"20.8","upperLimit":"24.8","value":"23.9"},{"groupId":"OG001","lowerLimit":"15.2","upperLimit":"22.4","value":"17.5"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"331"},{"groupId":"OG001","value":"163"}],"units":"Participants"}],"description":"Overall survival (OS) was defined as the time from the date of randomization to the date of death due to any cause. If there was no death reported for a participant before the data cutoff for OS analysis, OS was censored at the last contact date at which the participant was known to be alive.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants with HER2-low, unresectable, and/or metastatic breast cancer who were previously treated with chemotherapy were randomized to receive an intravenous infusion of DS8201a (initial dose of 5.4 mg/kg) over approximately 90 minutes. If there was no infusion-related reaction (IRR), T-DXd doses after the initial dose of 5.4 mg/kg were infused over a minimum of 30 minutes.","id":"OG000","title":"Trastuzumab Deruxtecan (T-DXd)"},{"description":"Participants with HER2-low, unresectable, and/or metastatic breast cancer who were previously treated with chemotherapy and randomized to a physician's choice (capecitabine, eribulin, gemcitabine, paclitaxel, and nab-paclitaxel) in which the dose, regimen, administration, and dose modification followed the label approved in the country of drug administration or the National Comprehensive Cancer Network guidelines.","id":"OG001","title":"Physician's Choice"}],"paramType":"MEDIAN","populationDescription":"Overall survival (OS) was assessed in the Hormone Receptor-Positive cohort of Full Analysis Set.","reportingStatus":"POSTED","timeFrame":"From the date of randomization up to the date of death due to any cause, up to approximately 3 years","title":"Overall Survival (OS) in the Hormone Receptor-Positive Cohort in Participants With HER2-low Breast Cancer","type":"SECONDARY","unitOfMeasure":"months"}